InspireMD AI Stock Analysis
Want to see NSPR full AI Analyst Report?
InspireMD (NSPR) AI Stock Analysis
InspireMD
(NASDAQ:NSPR)
InspireMD scores a 51, heavily weighed down by unsustainable cash burn, substantial net losses, and poor traditional valuation metrics. While recent FDA approval for CGuard Prime offers a critical growth catalyst and technicals show short-term bullish momentum, looming liquidity risks and the urgent need for external financing keep the overall stock profile highly speculative.
InspireMD Key Performance Indicators (KPIs)
Revenue by GeographyBreaks down where the company earns sales across countries and regions, showing which markets drive current revenue. For a small medical-device firm like InspireMD, geographic concentration highlights dependence on a few markets, distributors, or regulatory approvals, while expansion into new regions points to commercial traction and growth potential. Also signals exposure to currency moves, local reimbursement and healthcare funding, and where future upside or downside is most likely to occur.
Revenue has been dominated by the 'Other' bucket and steady European markets, but two structural shifts stand out: first commercial revenue in the U.S. appears only in late‑2025—an important commercialization inflection if sustained—and Russia’s contribution disappears in 2025, removing a prior revenue source (and geopolitical risk). Italy and Poland show healthy regional expansion; monitor whether U.S. momentum can replace lost Russian sales and whether 'Other' is truly diversified or a concentration risk.
The FlyInspireMD (NSPR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $37.19M
- Dividend Yield
- ―
- Average Volume (3M)
- 196.93K
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- -0.36
- Revenue Growth
- 53.42%
- EPS Growth
- 22.08%
- Country
- US
- Employees
- 127
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
InspireMD Business Overview & Revenue Model
Company Description
InspireMD, Inc., an Israel-based medical technology company established in 2005, specializes in creating and commercializing advanced medical devices. Its core expertise lies in the proprietary MicroNet stent platform technology, engineered to addres...
InspireMD Earnings Call Summary
The call was broadly positive, driven by FDA approval of CGuard Prime for TCAR, strong pivotal-trial results, an expanded U.S. market opportunity, immediate commercial launch readiness, international growth, and progress across the product pipeline. These positives were tempered by an 11% decline in total revenue, minimal U.S. sales following the voluntary recall, substantially lower gross margin, reduced cash and securities, a 20% workforce reduction, and the need for additional financing. Overall, management conveyed confidence in the company's next growth phase while acknowledging meaningful financial and execution work ahead.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
InspireMD expects to immediately pursue an approximately 40,000 annual procedure expansion in its U.S. addressable market, with CGuard Prime product already shipping and cases expected to begin immediately; it currently anticipates an FDA submission for the CGuard Prime 135 CAS delivery system before year's end and reentry of this platform in the first half of 2027, subject to regulatory review and approval; it currently expects a planned release of its proprietary micro puncture kit early Q1 2027; CGUARDIANS III enrollment is active, with timelines discussed for end of 2027 continuing to hold; and it expects incremental savings starting in Q4 and carrying over into the first several quarters of next year, with incremental investments again in sales and marketing in the back half of the year depending on the sales ramp and progress in launching CGuard Prime 80.
InspireMD Financial Statement Overview
Summary
InspireMD's financials reflect severe liquidity risks and heavy unprofitability. Despite a clean balance sheet with minimal debt, staggering net losses (-$38.5M TTM) and massive cash burn (-$41.2M TTM) threaten operational viability. KPI insights confirm that while international markets provide vital revenue stability, the U.S. segment has struggled recently, underscoring the urgent need for external funding and potential shareholder dilution.
Income Statement
15Very NegativeBalance Sheet
42NeutralCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.84M | 8.98M | 7.01M | 6.21M | 5.17M | 4.50M |
| Gross Profit | 1.96M | 2.65M | 1.51M | 1.81M | 1.12M | 754.00K |
| EBITDA | -37.86M | -48.25M | -31.67M | -19.62M | -18.27M | -14.55M |
| Net Income | -38.50M | -48.79M | -32.01M | -19.92M | -18.49M | -14.92M |
Balance Sheet | ||||||
| Total Assets | 44.64M | 69.40M | 46.81M | 47.64M | 24.65M | 39.71M |
| Cash, Cash Equivalents and Short-Term Investments | 30.42M | 54.21M | 34.64M | 39.02M | 17.80M | 34.04M |
| Total Debt | 1.97M | 3.29M | 2.34M | 1.59M | 1.61M | 1.20M |
| Total Liabilities | 13.13M | 14.20M | 10.72M | 8.14M | 7.26M | 6.18M |
| Stockholders Equity | 31.51M | 55.20M | 36.09M | 39.50M | 17.39M | 33.53M |
Cash Flow | ||||||
| Free Cash Flow | -42.46M | -36.77M | -23.27M | -16.76M | -16.02M | -13.55M |
| Operating Cash Flow | -41.21M | -35.10M | -21.87M | -16.38M | -15.54M | -13.21M |
| Investing Cash Flow | -8.15M | -30.56M | 12.64M | -16.09M | 8.44M | -22.46M |
| Financing Cash Flow | 52.93M | 55.57M | 18.45M | 37.53M | -140.00K | 35.03M |
InspireMD Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Positive. The current price of 0.77 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.63, and below the 200-day MA of 1.03, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 63.97 is Neutral, neither overbought nor oversold. The STOCH value of 91.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NSPR.
InspireMD Risk Analysis
InspireMD disclosed 46 risk factors in its most recent earnings report. InspireMD reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksInspireMD Peers Comparison
Overall Rating
ANIK56Neutral
APYX53Neutral- NSPR51Neutral
VANI42Neutral
XTNT41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ANIK | 56Neutral | $186.86M | -107.26 | -1.28% | ― | 9.42% | 94.37% |
| APYX | 53Neutral | $126.37M | -14.31 | -70.78% | ― | 24.35% | 46.90% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NSPR | 51Neutral | $37.19M | -1.52 | -79.21% | ― | 53.42% | 22.08% |
| VANI | 42Neutral | $101.93M | -2.75 | -161.39% | ― | ― | 25.92% |
| XTNT | 41Neutral | $38.99M | -3.39 | -23.45% | ― | -14.27% | -132.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NSPR | InspireMD Inc | 0.77 | -1.34 | -63.32% | |
| ANIK | Anika Therapeutics, Inc. | 13.81 | 3.82 | 38.24% | |
| APYX | Apyx Medical | 2.89 | -1.01 | -25.90% | |
| VANI | Vivani Medical, Inc. | 0.98 | -0.44 | -30.77% | |
| XTNT | Xtant Medical Holdings Inc | 0.28 | -0.38 | -57.82% |
InspireMD Corporate Events
InspireMD FDA Approves CGuard Prime for TCAR Procedures
PositiveOn November 12, 2026, the U.S. Food and Drug Administration approved InspireMD’s Premarket Approval Supplement for the CGuard Prime TransCarotid Stent System for TCAR procedures. The 80 cm system can be used with an embolic protection system specifie...
InspireMD FDA Approves CGuard Prime, Restoring U.S. Market Access
PositiveOn November 12, 2026, InspireMD reported that the FDA had approved CGuard Prime for TCAR, returning the platform to the U.S. market and expanding its addressable opportunity by more than 35,000 procedures annually. Data from the CGUARDIANS II pivotal...
InspireMD Amends Warrants to Support CGuard Prime Launch
PositiveOn September 21, 2026, InspireMD amended certain Series J and Series K warrants originally issued in a May 2023 private placement, covering roughly 4.8 million Series J and 9.5 million Series K underlying shares held by participating investors, inclu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026